Contact SCGE




Gene Therapy Trial Report

Summary

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis


NCTID NCT05835895 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Osteoarthritis, Knee
Disease Ontology Term DOID:8398
Compound Name GNSC-001
Compound Description AAV-CMV-IL1RN
Sponsor Genascence Corporation
Funder Type Industry
Recruitment Status
Active not recruiting
Enrollment Count 67 (ACTUAL)
Results Posted Not Available

Therapy Information


Target Gene/Variant IL1RN
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Overexpression of protective allele/gene
Route of Administration Intraarticular
Drug Product Type Viral vector
Delivery System Viral transduction
Vector Type AAV2.5
Editor Type none
Dose 1 1E11 vg/knee
Dose 2 1E12 vg/knee
Dose 3 1E13 vg/knee

Study Record Dates


Current Stage Phase1
Submit Date 2023-04-19
Completion Date 2029-05
Last Update 2025-08-01

Participation Criteria


Eligible Age 40 Years - 75 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL
Eligibility Criteria
Key Inclusion Criteria: * OA in at least one knee (the 'target knee'), confirmed using centrally read X-ray with a Kellgren-Lawrence (KL) score of 2 or 3 * Western Ontario \& McMaster University Osteoarthritis Index (WOMAC) pain score ≥ 20 (on a 50-point numerical rating scale) in the target knee during the seven days prior to Screening * Persistent moderate to severe symptoms in the target knee, despite failure or intolerance of a 3-month trial of at least 2 conservative therapies (e.g., activity modification, weight loss, physical therapy, opioids, and anti-inflammatory medications, and injection of hyaluronic acid or steroids) * Successful extraction of synovial fluid at Screening * Negative pregnancy test at Screening and Baseline (subjects of childbearing potential \[SOCBP\]) Key Exclusion Criteria: * Current or documented history of inflammatory arthritis (such as gout or rheumatoid arthritis), inflammation of connective tissue, or other immunological disease * Any form of joint degeneration as part of another syndrome (e.g., Ehler's Danlos, Stickler syndrome, etc.) * Surgery in the target knee within the 6 months prior to screening * Previous partial or total joint replacement in target knee * Significant and clinically evident malalignment of the target knee that would impact the subject's function, as determined by the Investigator * Body mass index (BMI) \> 38 kg/m2 * Clinically significant abnormal laboratory values at Screening in laboratory parameters that in the opinion of the Investigator, could represent a potential risk to participant safety: * Plans to have, elective surgery of other joints or spine or intra-articular injections in the target knee, within the next 12 months
View Inclusion and Exclusion Criteria at ClinicalTrials.gov

Locations


No.of Trial Sites 9
Locations United States

Regulatory Information


Has US IND True
FDA Designations Fast Track, Regenerative Medicine Advanced Therapy
Recent Updates Initial data for Phase 1b trial expected Q4 2024

Resources/Links